Allergan Aesthetics, an AbbVie company, said Health Canada has approved Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows, known as glabellar lines, in adult patients.
The company said Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines.
"Health Canada's approval of Boey® marks an important scientific and regulatory milestone in advancing toxin science. As the world's first approval of a botulinum neurotoxin based on serotype E in aesthetics, Boey® represents a meaningful advancement in aesthetic medicine - a fast-acting neurotoxin with a differentiated profile that expands the treatment options for clinicians and patients", said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie.
Allergan Aesthetics also cited findings from a new company survey showing 80% of people are open to learning about new treatments to get the results they want and 79% wish they could temporarily preview the outcome of an aesthetic treatment. According to the company, interest in facial injectables has grown, but many patients remain hesitant because of uncertainty around treatment outcomes and concern about committing to long-lasting results.
The company said Boey® was developed for those patients as a new way to experience neurotoxin treatment.
"Boey® represents an important new advancement for patients and healthcare professionals, addressing a key need in aesthetic neurotoxins. With its truly differentiated profile, Boey® is redefining aesthetics and expanding what's possible by giving practitioners another option to tailor treatment to individual needs and goals, specifically, the ability to try a toxin without the long-term commitment", said Nicole Mowad-Nassar, senior vice president, AbbVie and president, global Allergan Aesthetics. "Allergan Aesthetics is proud to bring this innovation to Canada first and to continue advancing options that help shape the future of aesthetic medicine."
